Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed ninety-six subjects (27 cognitively normal, 49 mild cognitive impairment, and 20 AD dementia) who underwent [<sup>18</sup>F]FDG and [<sup>18</sup>F]Florbetapir positron emission tomography (PET) as well as magnetic resonance imaging (MRI) with diffusion tensor imaging.
|
30414086 |
2019 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both 18F-FDG and 18F-florbetapir could successfully detect subjects with dementia (p < 0.001).
|
31322568 |
2019 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
[F]FDG PET may be useful as a non-invasive diagnostic modality in differentiating the two posterior cortical dementias, despite significant overlap.
|
31633646 |
2019 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to investigate the association between cerebrospinal fluid (CSF), magnetic resonance imaging (MRI), amyloid- and <sup>18</sup>F-FDG positron emission tomography (PET) measures at baseline, in relation to cognitive changes and conversion to AD dementia over a short-term (12-month) period.
|
30927601 |
2019 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [<sup>18</sup>F]FDG PET.
|
30094462 |
2019 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the clinically implemented MRAC methods, Dixon<sub>Bone</sub> should be preferred for diagnostic assessment of dementia with [<sup>18</sup>F]FDG PET/MRI.
|
31446507 |
2019 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although accurate differential diagnosis of dementia can be achieved by imaging disease-specific patterns of cerebral glucose metabolism with [F]fluorodeoxyglucose ([F]FDG)-PET, the diagnostic impact of [F]FDG-PET in primary psychiatric disorders is limited.
|
31107281 |
2019 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, in the opinion of the majority of the panellists, FDG PET is a clinically useful imaging biomarker for idiopathic PD and atypical parkinsonism associated with dementia.
|
29779045 |
2018 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia.
|
29713763 |
2018 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
PET using FDG is a critical tool for evaluation of dementias, with characteristic patterns of hypometabolism suggesting specific diagnoses.
|
29232244 |
2018 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To update the evidence and reassess the accuracy of 18F-FDG-PET for detecting people with MCI at baseline who would clinically convert to Alzheimer's disease (AD) dementia at follow-up.
|
30010119 |
2018 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since fluorodeoxyglucose positron emission tomography (FDG PET) measurements of the regional cerebral metabolic rate of glucose (rCMRgl) provide a sensitive and specific marker of neurodegenerative disease progression, we sought to investigate the longitudinal pattern of rCMRgl in amyloid-positive persons with mild cognitive impairment (MCI) and dementia, hypothesizing asymmetric declines of cerebral glucose metabolism.
|
30101060 |
2018 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, <sup>18</sup>F-FDG PET is a useful tool when the cause for dementia remains unclear and different diagnosis would lead to different treatment approaches.
|
29512075 |
2018 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Qualitative agreement and diagnostic performance of arterial spin labelling MRI and FDG PET-CT in suspected early-stage dementia: Comparison of arterial spin labelling MRI and FDG PET-CT in suspected dementia.
|
28551486 |
2018 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
At a group level, patients with AD (prodromal or dementia) showed unchanged [<sup>18</sup>F]THK5317 retention over time, in contrast to significant decreases in [<sup>18</sup>F]FDG uptake in temporoparietal areas.
|
28507319 |
2018 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the utility of 18F-FDG-PET to differentiate flortaucipir tau PET negative from flortaucipir positive amnestic mild cognitive impairment and dementia and used an autopsy confirmed cohort to test the hypothesis that hippocampal sclerosis might account for the observed pattern.
|
29538658 |
2018 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discriminative performance (prodromal vs Alzheimer's disease dementia) of [<sup>18</sup>F]THK5317 (early-phase SUVr and R<sub>1</sub>) was compared with that of [<sup>11</sup>C]PIB (early-phase SUVr and R<sub>1</sub>) and [<sup>18</sup>F]FDG.
|
27107028 |
2017 |